Immunotherapy, a treatment that helps the body’s own immune system fight cancer, has revolutionized cancer care. One promising approach involves engineering T cells, a type of immune cell, to recognize and attack cancer. However, some tumors evade this treatment by hiding the proteins that T cells need to detect them. This limits the effectiveness of current T cell therapies. Our research aims to overcome this challenge by equipping T cells with an additional ability to recognize and destroy cancer cells, even when these proteins are absent. This approach has the potential to improve treatment outcomes, especially for aggressive cancers that resist other immunotherapies. By enhancing the ability of T cells to adapt to different tumor environments, our work brings us closer to more effective, long-lasting cancer treatments. If successful, this strategy could offer new hope for patients who currently have limited options.